Segmed and Verily Partner to Accelerate AI Health Research via New Data Exchange

Segmed, Inc. and Verily have announced a strategic partnership to bring de-identified, diagnostic-grade medical imaging data to Verily’s self-serve precision health platform. This collaboration allows researchers to access curated datasets within the Pre Exchange and Workbench environments to support AI development and precision medicine. By integrating these resources, the companies aim to lower the technical and legal barriers currently hindering rapid biomedical discovery. The initial rollout features a high-value dataset focused on breast cancer research, specifically Digital Breast Tomosynthesis (DBT) exams. This cohort includes longitudinal patient data and biopsy-proven results, providing the ground truth necessary for training sophisticated AI models. This launch draws from Segmed’s broader network of approximately 150 million de-identified exams across modalities like MRI, CT, and PET.

"Advanced imaging data plays a critical role in precision medicine, particularly when combined with clinical and other biomedical data modalities," said David Gascoigne, CEO of Segmed.

He emphasized that the partnership expands responsible access to high-quality data to help researchers generate insights faster. Bharat Rajagopal, Chief Revenue Officer at Verily, added that the integration empowers researchers with the multimodal resources needed to unlock new health discoveries.

The move aligns with Verily’s ongoing strategic transition to become a primary AI and data infrastructure provider. By hosting Segmed’s data, Verily’s Pre platform serves as a digital marketplace where researchers can browse and analyze data in situ. This infrastructure eliminates the need for complex data transfers and lengthy bilateral negotiations, favoring a software-as-a-service model for clinical research.

Segmed continues to scale its operations following a recent leadership transition and the securing of independent HIPAA Expert Determination. This regulatory milestone ensures that their de-identification processes for both pixel and text data meet the highest privacy standards. The company’s global network spans five continents, providing a diverse foundation for equitable healthcare advancements through biopharmaceutical R&D.